ACP
BMY icon

Argyle Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Argyle Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$382K Buy
6,628
+146
+2% +$8.38K 0.24% 109
2026
Q1 		$393K Sell
6,482
-3,317
-34% -$193K 0.28% 99
2025
Q4 		$529K Sell
9,799
-473
-5% -$22.8K 0.39% 80
2025
Q3 		$463K Buy
10,272
+687
+7% +$32.1K 0.33% 89
2025
Q2 		$444K Sell
9,585
-3,764
-28% -$185K 0.37% 80
2025
Q1 		$814K Sell
13,349
-836
-6% -$48.7K 0.7% 50
2024
Q4 		$802K Buy
+14,185
New +$793K 0.69% 49

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Argyle Capital Partners's BMY Position: Q2 2026 in Review

Argyle Capital Partners increased its Bristol-Myers Squibb (BMY) stake by 2.3% in Q2 2026, buying an estimated $8.38K and bringing the position to 6,628 shares worth $382K. The position accounts for 0.24% of the portfolio, ranked #109.

Argyle Capital Partners first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $814K in Q1 2025. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Argyle Capital Partners held 6,628 shares of Bristol-Myers Squibb worth $382K as of Q2 2026.
  • Argyle Capital Partners bought 146 Bristol-Myers Squibb shares in Q2 2026, an estimated $8.38K.
  • Bristol-Myers Squibb made up 0.24% of Argyle Capital Partners's portfolio in Q2 2026, its #109 holding.
  • Argyle Capital Partners first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
  • Argyle Capital Partners's Bristol-Myers Squibb position peaked at $814K in Q1 2025.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Argyle Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.